HOOKIPA Pharma to Report First Quarter 2021 Financial Results on Wednesday, May 12, 2021
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is set to report its first quarter 2021 financial results on May 12, 2021. The company specializes in developing immunotherapeutics utilizing its proprietary arenavirus platform, which targets immune system activation. HOOKIPA's products include HB-201 and HB-202 for HPV-related cancers and HB-101, a vaccine for Cytomegalovirus in kidney transplant patients, both in clinical trials. HOOKIPA has also partnered with Gilead Sciences to explore HIV and Hepatitis B treatments.
- HOOKIPA's proprietary arenavirus platform shows potential for strong immune responses.
- Lead product candidates HB-201 and HB-202 are advancing in Phase 1/2 clinical trials for HPV-related cancers.
- Collaboration with Gilead Sciences may enhance research capabilities in treating HIV and Hepatitis B.
- None.
NEW YORK and VIENNA, Austria, May 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2021 financial results before the market opens on Wednesday, May 12, 2021.
The Company will not be conducting a conference call in conjunction with this earnings release.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.
HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.
Find out more about HOOKIPA online at www.hookipapharma.com.
| For further information, please contact: | |
| Media | Investors |
| Nina Waibel | Matt Beck |
| Senior Director - Communications | Executive Director - Investor Relations |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com |
FAQ
When will HOOKIPA Pharma announce its Q1 2021 financial results?
What are the lead product candidates of HOOKIPA Pharma?
What clinical trials is HOOKIPA currently involved in?
What collaboration has HOOKIPA entered regarding infectious diseases?
